UroGen stock rocketed Thursday on "unprecedented" test results for its bladder cancer treatment, a gel-based drug that avoids surgically removing tumors.
After three months, 79.6% of patients treated with UroGen Pharma's (URGN) drug had a complete response, meaning evidence of their tumors disappeared. But what's unprecedented, says the company, is patients had an 82.3% chance of maintaining that response for at least a year.
Chief Executive Liz Barrett estimates that 82,000 patients live with this highly recurrent form of cancer each year in the U.S. These patients have bladder cancer that doesn't penetrate muscle tissue. Their cancer is considered intermediate risk.
https://www.investors.com/news/technology/urogen-stock-bladder-cancer-treatment/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.